Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283814 | 0.78 | LMNA (0.53) | KMT2AGAATSHRLMNA | |
| SCHEMBL5295531 | 0.78 | MEN1 (0.51) | SMN1; SMN2KMT2AMEN1GAATSHR | |
| SCHEMBL5286439 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMEN1GAALMNA | |
| SCHEMBL18214843 | 0.72 | HTT (0.44) | CDK8DAOFEN1 | |
| SCHEMBL6690688 | 0.69 | CDK8 (0.38) | CDK8DAOGAA | |
| SCHEMBL26334570 | 0.69 | CDK8 (0.38) | CDK8DAOKMT2AFEN1GAA | |
| SCHEMBL26334572 | 0.68 | CDK8 (0.38) | CDK8DAOKMT2AFEN1GAA | |
| SCHEMBL5283894 | 0.67 | VHL (0.49) | SMN1; SMN2KMT2AMEN1TSHRLMNA | |
| SCHEMBL5289208 | 0.66 | RIPK1 (0.39) | DAOSMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL19006409 | 0.66 | CYP4F2 (0.45) | KMT2AMEN1GAATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | CDK8 3844/4885DAO 1438/4885SMN1; SMN2 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.